ClinicalTrials.gg
Not yet recruitingNCT07638111SENSILNSUpdated Jun 10, 2026

SENSILINS: Impact of Cephalic Phase Insulin Release Induced by an Environmental Food Odor Stimulus on Glucose Homeostasis According to Insulin Sensitivity Level

An interventional study of Pleasant Food Odor Stimulation and Control Environmental Condition in Obesity & Overweight and Insulin Resistance Syndrome, sponsored by Hospices Civils de Lyon. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Basic science

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Obesity by Hospices Civils de Lyon — 11 open to participants now, 12 under way, 1 of them phase 3. Obesity · Hospices Civils de Lyon.

Planned enrollment
21st of 23
20 · median 70
Started
2026
with 3 others
No phase
20 of 32
9 open now
Primary completion
2027-07
later than 6 of 11 live
Registered
30th of 32
by date

Among the 32 studies in Obesity by Hospices Civils de Lyon, this one is the 21st largest by planned enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2026, is one of 20 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 30th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

11 of the 32 studies in Obesity by Hospices Civils de Lyon are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Obesity by Hospices Civils de Lyon, or all of them as a file.
02

Study summary

This single-center, randomized, single-blind, 2-period crossover interventional study will evaluate whether exposure to a pleasant food odor 10 minutes before a 75 g oral glucose tolerance test (OGTT) modifies glucose homeostasis in adults with different metabolic phenotypes. Participants will undergo two experimental conditions in random order: food odor stimulation and control condition without odor, separated by a 4-week washout. The main objective is to quantify the within-subject effect of food odor stimulation on the incremental area under the glucose curve (iAUC) from 0 to 120 minutes during OGTT and to assess whether this effect differs according to metabolic status. Two predefined groups will be enrolled: adults without overweight and without insulin resistance, and adults with class I obesity and low-to-moderate insulin resistance. Secondary objectives include characterization of cephalic phase insulin release (CPIR), C-peptide and GLP-1 responses, glycemic kinetics, associations between CPIR and metabolic responses, and participant acceptability of the test environment and olfactory stimulation. A plasma biobank will be constituted from part of the collected samples for future research.

Read the detailed description

Recent experimental and translational data suggest that olfactory cues may contribute to metabolic regulation through anticipatory cephalic phase responses. Cephalic phase insulin release (CPIR) is an early preabsorptive insulin response triggered by sensory food-related stimuli before nutrient absorption. Preclinical data generated by the study team suggest that food-odor-induced CPIR involves an olfactory bulb-pancreas axis and may be altered in obesity. The present study is designed to investigate, in humans, whether a pleasant appetitive food odor delivered before glucose ingestion can induce measurable CPIR and improve post-load glucose handling.

The study uses a randomized AB/BA crossover design with two experimental visits after screening and inclusion. During one visit, participants are exposed to prerecorded food odor diffusion using a ScentRealm collar starting at T-10 minutes before ingestion of a 75 g glucose solution at T0. During the control visit, the same testing environment is maintained without odor stimulation. Serial blood sampling is performed before and after glucose ingestion to characterize glucose, insulin, C-peptide, and GLP-1 kinetics. The washout period is 4 weeks (±3 days), partly to align visits within the same menstrual cycle phase in women when applicable. The trial includes 20 adults aged 18 to 50 years: 10 without overweight and insulin-sensitive, and 10 with obesity and low-to-moderate insulin resistance defined using HOMA-IR.

03

Conditions studied

  • Obesity & Overweight
  • Insulin Resistance Syndrome

Keywords

  • Glucose Homeostasis
  • Cephalic Phase Insulin Release
  • Food odor
  • Olfaction
  • Oral glucose tolerance test
  • Insulin secretion
  • GLP-1
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 50 years inclusive
  • Stable body weight during the previous 3 months (±5% of total body weight)
  • Willing to comply with the full study protocol
  • Sedentary lifestyle or stable regular physical activity, with agreement to keep this unchanged throughout the study
  • Able to understand study information, read and write French, and provide written
  • Affiliated with a social security scheme or equivalent
  • Non-smoker and non-vaper
  • Willing not to take dietary supplements, probiotics, prebiotics, or laxatives for 10 days before each visit
  • For women of : negative serum pregnancy test; not pregnant and not breastfeeding
  • Mean score between 1 and 2 on the 3 specific CiTAS questionnaire statements used as inclusion criteria
  • ETOC flash olfactory screening: able to detect the odor-containing vial among 4 presented vials for all 7 odors tested
  • Able to identify the madeleine odor used in the study
  • Rated pleasantness/appetence of the madeleine odor above 1/9
  • For the no-overweight group: 19 to \<25 kg/m² and HOMA-IR \<1.7
  • For the obesity group: BMI 30 to \<35 kg/m² and low-to-moderate insulin resistance based on HOMA-IR [protocol inconsistency to resolve; see note below]

Exclusion criteria

Exclusion Criteria

  • Unstable medical or psychological conditions that could impair compliance, safety, or study participation in the investigator's judgment
  • Alcohol consumption >30 g/day, or established abuse/dependence on another drug
  • Ongoing exclusion period from another study listed in the national volunteer file
  • Legal protection measure (guardianship/curatorship)
  • Deprivation of liberty by judicial or administrative decision
  • Exceeded annual compensation limit for research participation
  • Lack of valid required health documentation in the event of exceptional governmental epidemic measures
  • Blood donation within 2 months before inclusion visit
  • Limited venous access making repeated blood sampling/catheter placement difficult
  • Current or permanent anosmia or olfactory disorder
  • Type 1 or type 2 diabetes, treated or untreated
  • History of gestational diabetes
  • Known or treated hypertension
  • Blood pressure >160 [unit missing; likely mmHg systolic threshold]
  • Dyslipidemia, treated or untreated
  • Triglycerides >3 mmol/L
  • Allergic rhinitis
  • Nasosinusal polyposis
  • History of intestinal or abdominal surgery except appendectomy or simple hernia repair
  • History of ENT or neurological surgery
  • Severe eating disorder (for example anorexia, bulimia, binge-eating disorder, night eating)
  • Any pathology detected on clinical examination or medical interview judged by the investigator to interfere with study endpoints or participant safety
  • Any biological abnormality judged by the investigator to interfere with study endpoints or participant safety
  • Use of treatments likely to interfere with study measurements, for example antidepressants, antiepileptics, neuroleptics, CPAP treatment for sleep apnea, nasal spray medications, or anti-obesity drug treatment, according to investigator judgment
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
20 participants (estimated)

Study arms

  • Active comparator
    Food Odor Stimulation

    Participants are exposed to a pleasant appetitive food odor delivered through a ScentRealm collar beginning 10 minutes before ingestion of a 75 g oral glucose load and continuing according to a prerecorded sequence during the metabolic test visit.

    Behavioral: Pleasant Food Odor Stimulation · Behavioral: Control Environmental Condition

  • Placebo comparator
    Control Condition

    Participants undergo the same standardized metabolic test visit and OGTT procedures in the same test environment without food odor stimulation.

    Behavioral: Pleasant Food Odor Stimulation · Behavioral: Control Environmental Condition

Interventions

  • BehavioralPleasant Food Odor Stimulation

    Exposure to an experimentally selected appetitive food odor (madeleine odor) delivered using a programmable ScentRealm collar in a standardized test room beginning at T-10 minutes before OGTT.

  • BehavioralControl Environmental Condition

    Standardized testing environment identical to the experimental visit but without diffusion of the appetitive food odor.

06

What researchers measure

Primary outcomes

  1. Within-subject difference in glucose incremental area under the curve (iAUC) from 0 to 120 minutes during OGTT

    Primary endpoint is the mean within-subject difference between food odor and control conditions in glucose incremental area under the curve from 0 to 120 minutes after oral glucose ingestion. Glucose iAUC will be calculated using the trapezoidal method, baseline-adjusted to glucose at T0. The main analysis will also assess the interaction between condition (odor vs control) and metabolic status (no overweight/insulin-sensitive vs obesity with low-to-moderate insulin resistance). Unit should be specified in the statistical analysis plan according to assay reporting (for example mmol/L×min or mg/dL×min).

    Time frame: During each experimental visit, from 0 to 120 minutes after ingestion of the 75 g oral glucose load

Secondary outcomes

  1. Preabsorptive and early post-ingestion insulin iAUC as a measure of cephalic phase insulin release

    Incremental area under the curve for insulin during the pre-ingestion and early post-ingestion period (0 to 15 minutes), compared by condition and metabolic status. Additional CPIR-related metrics include latency, peak concentration, slope, and percentage of responders. Unit to specify according to assay output (for example µIU/mL×min or pmol/L×min).

    Time frame: From pre-OGTT odor exposure through 15 minutes after glucose ingestion during each experimental visit

  2. Preabsorptive and early post-ingestion C-peptide iAUC

    Incremental area under the curve for C-peptide during the pre-ingestion and early post-ingestion period (0 to 15 minutes), compared by condition and metabolic status. Additional metrics include latency, peak concentration, slope, and percentage of responders. Unit to specify according to assay output.

    Time frame: From pre-OGTT odor exposure through 15 minutes after glucose ingestion during each experimental visit

  3. Glycemic kinetic response during OGTT - Δmax

    Effect of condition and metabolic status on glycemic maximum change from baseline (Δmax)

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  4. Glycemic kinetic response during OGTT - Time to peak

    Effect of condition and metabolic status on the necessary amount of time to reach glycemic peak in minutes

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  5. Glycemic kinetic response during OGTT - Growth curve slope

    Effect of condition and metabolic status on the slope of the glycemic growth curve from baseline

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  6. Glycemic kinetic response during OGTT - Decay curve slope

    Effect of condition and metabolic status on the slope of the glycemic decay curve from the maximum (peak)

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  7. Glycemic kinetic response during OGTT - ultradian oscillation indices

    Effect of condition and metabolic status on ultradian oscillation indices

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  8. Glycemic kinetic response during OGTT - iAUC (0 to 120 min)

    Effect of condition and metabolic status on Incremental Area Under the Curve (IAUC) from 0 to 120 min for glucose

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  9. Glycemic kinetic response during OGTT - early glucose iAUC (0-30min)

    Effect of condition and metabolic status on glucose Incremental Area Under the Curve (IAUC) from 0 to 30 min

    Time frame: From 0 to 30 minutes after glucose ingestion during each experimental visit

  10. Glycemic kinetic response during OGTT - late glucose iAUC (30-120 min)

    Effect of condition and metabolic status on glucose Incremental Area Under the Curve (IAUC) from 30 to 120 min

    Time frame: From 30 to 120 minutes after glucose ingestion during each experimental visit

  11. Hormonal response parameters for insulin during OGTT - iAUC (0-120 min)

    Total Incremental Area Under the Curve (iAUC) from 0 to 120 minutes

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  12. Hormonal response parameters for insulin during OGTT - iAUC (0-30min)

    Insulin Incremental Area Under the Curve (IAUC) from 0 to 30 min

    Time frame: From 0 to 30 minutes after glucose ingestion during each experimental visit

  13. Hormonal response parameters for insulin during OGTT - iAUC (30-120min)

    Insulin Incremental Area Under the Curve (IAUC) from 30 to 120 min

    Time frame: From 30 to 120 minutes after glucose ingestion during each experimental visit

  14. Hormonal response parameters for insulin during OGTT - Δmax

    The value of the maximum (peak) of the curve relative to the baseline value for insulin

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  15. Hormonal response parameters for insulin during OGTT - Time to peak

    Necessary amount of time for insulin to reach peak in minutes

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  16. Hormonal response parameters for insulin during OGTT - Growth curve slope

    Slope of the insulin growth curve from baseline

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  17. Hormonal response parameters for insulin during OGTT - Decay curve slope

    Slope of the insulin decay curve from the maximum (peak)

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  18. Hormonal response parameters for C-peptide during OGTT - iAUC (0-120min)

    C-peptide Incremental Area Under the Curve (IAUC) from 0 to 120 min

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  19. Hormonal response parameters for C-peptide during OGTT - iAUC (0-30min)

    C-peptide Incremental Area Under the Curve (IAUC) from 0 to 30 min

    Time frame: From 0 to 30 minutes after glucose ingestion during each experimental visit

  20. Hormonal response parameters for C-peptide during OGTT - iAUC (30-120min)

    C-peptide Incremental Area Under the Curve (IAUC) from 30 to 120 min

    Time frame: From 30 to 120 minutes after glucose ingestion during each experimental visit

  21. Hormonal response parameters for C-peptide during OGTT - Δmax

    The value of the maximum (peak) of the curve relative to the baseline value for C-peptide

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  22. Hormonal response parameters for C-peptide during OGTT - Time to peak

    Necessary amount of time for C-peptide to reach peak in minutes

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  23. Hormonal response parameters for C-peptide during OGTT - Growth curve slope

    Slope of the C-peptide growth curve from baseline

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  24. Hormonal response parameters for C-peptide during OGTT - Decay curve slope

    Slope of the C-peptide decay curve from the maximum (peak)

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  25. Hormonal response parameters for GLP-1 during OGTT - iAUC (0-120min)

    GLP1 Incremental Area Under the Curve (IAUC) from 0 to 120 min

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  26. Hormonal response parameters for GLP-1 during OGTT - iAUC (0-30min)

    GLP-1 Incremental Area Under the Curve (IAUC) from 0 to 30 min

    Time frame: From 0 to 30 minutes after glucose ingestion during each experimental visit

  27. Hormonal response parameters for GLP-1 during OGTT - iAUC (30-120min)

    GLP-1 Incremental Area Under the Curve (IAUC) from 30 to 120 min

    Time frame: From 30 to 120 minutes after glucose ingestion during each experimental visit

  28. Hormonal response parameters for GLP-1 during OGTT - Δmax

    The value of the maximum (peak) of the curve relative to the baseline value for GLP-1

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  29. Hormonal response parameters for GLP-1 during OGTT - Time to peak

    Necessary amount of time for GLP-1 to reach peak in minutes

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  30. Hormonal response parameters for GLP-1 during OGTT - Growth curve slope

    Slope of the GLP-1 growth curve from baseline

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  31. Hormonal response parameters for GLP-1 during OGTT - Decay curve slope

    Slope of the GLP-1 decay curve from the maximum (peak)

    Time frame: From 0 to 120 minutes after glucose ingestion during each experimental visit

  32. Correlation between CPIR characteristics and metabolic/hormonal responses

    Correlations between CPIR features and subsequent glucose response during OGTT (including glucose iAUC 0-120 and early/late components) and hormonal quantitative/kinetic responses, including assessment of interaction with metabolic status.

    Time frame: Assessed using measurements collected during each experimental visit up to 120 minutes after glucose ingestion

  33. Participant-rated appreciation of the experimental odor

    Appreciation of the experimental odor and related emotions assessed using Likert scales at the end of the odor visit, with comparison by condition and metabolic status where applicable. Exact scale range and anchor wording are not provided in the available protocol text.

    Time frame: Week 2 ; Week 4

  34. Participant-rated acceptability of the test environment - Temperature

    Acceptability and appreciation of the temperature of the environment assessed using Likert scales and free-text fields. Comparison by condition and metabolic status. Scale range should be entered exactly as used in source questionnaires.

    Time frame: Week 2 ; Week 4

  35. Participant-rated acceptability of the test environment - Lighting

    Acceptability and appreciation of the lighting of the environment assessed using Likert scales and free-text fields. Comparison by condition and metabolic status. Scale range should be entered exactly as used in source questionnaires.

    Time frame: Week 2 ; Week 4

  36. Participant-rated acceptability of the test environment - Sound

    Acceptability and appreciation of the sound of the environment assessed using Likert scales and free-text fields. Comparison by condition and metabolic status. Scale range should be entered exactly as used in source questionnaires.

    Time frame: Week 2 ; Week 4

  37. Participant-rated acceptability of the test environment - Odor

    Acceptability and appreciation of the odor of the environment assessed using Likert scales and free-text fields. Comparison by condition and metabolic status. Scale range should be entered exactly as used in source questionnaires.

    Time frame: Week 2 ; Week 4

07

Study locations

1 site
  • Centre de Recherche en Nutrition Humaine Rhône-Alpes, Centre Hospitalier Lyon Sud
    Pierre-Bénite, 69495, France
08

References and documents

Individual participant data

Plan to share: Undecided — No IPD sharing statement is provided in the available protocol for the moment.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Jul 2027, 13 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 13 months is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2026
First posted
Jun 10, 2026
StartEst.
Jun 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07638111
Responsible party
Sponsor
First posted
Jun 10, 2026
Start date
Jun 2026 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Jun 10, 2026

Study contacts

Anne Laure MD CASTELL, Dr
Contact
anne-laure.castell@chu-lyon.fr
+33 4 78 86 19 72 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion